|
Gene: DIRC2 |
Gene summary for DIRC2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DIRC2 | Gene ID | 84925 |
Gene name | solute carrier family 49 member 4 | |
Gene Alias | DIRC2 | |
Cytomap | 3q21.1 | |
Gene Type | protein-coding | GO ID | GO:0000323 | UniProtAcc | Q96SL1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84925 | DIRC2 | P1T-E | Human | Esophagus | ESCC | 2.33e-02 | 3.35e-01 | 0.0875 |
84925 | DIRC2 | P2T-E | Human | Esophagus | ESCC | 3.18e-24 | 3.66e-01 | 0.1177 |
84925 | DIRC2 | P4T-E | Human | Esophagus | ESCC | 1.61e-11 | 3.00e-01 | 0.1323 |
84925 | DIRC2 | P5T-E | Human | Esophagus | ESCC | 4.01e-11 | 2.30e-01 | 0.1327 |
84925 | DIRC2 | P8T-E | Human | Esophagus | ESCC | 9.01e-20 | 2.77e-01 | 0.0889 |
84925 | DIRC2 | P9T-E | Human | Esophagus | ESCC | 7.73e-05 | 1.58e-01 | 0.1131 |
84925 | DIRC2 | P10T-E | Human | Esophagus | ESCC | 5.97e-12 | 2.23e-01 | 0.116 |
84925 | DIRC2 | P11T-E | Human | Esophagus | ESCC | 1.12e-02 | 2.45e-01 | 0.1426 |
84925 | DIRC2 | P12T-E | Human | Esophagus | ESCC | 3.68e-11 | 1.45e-01 | 0.1122 |
84925 | DIRC2 | P15T-E | Human | Esophagus | ESCC | 1.99e-06 | 1.83e-01 | 0.1149 |
84925 | DIRC2 | P16T-E | Human | Esophagus | ESCC | 5.06e-11 | 1.06e-01 | 0.1153 |
84925 | DIRC2 | P20T-E | Human | Esophagus | ESCC | 3.14e-08 | 1.39e-01 | 0.1124 |
84925 | DIRC2 | P21T-E | Human | Esophagus | ESCC | 1.33e-19 | 2.27e-01 | 0.1617 |
84925 | DIRC2 | P22T-E | Human | Esophagus | ESCC | 2.51e-22 | 4.38e-01 | 0.1236 |
84925 | DIRC2 | P23T-E | Human | Esophagus | ESCC | 1.29e-15 | 4.74e-01 | 0.108 |
84925 | DIRC2 | P24T-E | Human | Esophagus | ESCC | 3.08e-07 | 1.54e-01 | 0.1287 |
84925 | DIRC2 | P26T-E | Human | Esophagus | ESCC | 4.81e-15 | 3.17e-01 | 0.1276 |
84925 | DIRC2 | P27T-E | Human | Esophagus | ESCC | 4.82e-10 | 8.29e-02 | 0.1055 |
84925 | DIRC2 | P28T-E | Human | Esophagus | ESCC | 1.30e-23 | 3.92e-01 | 0.1149 |
84925 | DIRC2 | P30T-E | Human | Esophagus | ESCC | 1.66e-11 | 4.74e-01 | 0.137 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Liver | Cyst | |
Lung | IAC | |
Lung | AIS | |
Lung | AAH | |
Lung | MIAC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DIRC2 | SNV | Missense_Mutation | c.454N>G | p.Gln152Glu | p.Q152E | Q96SL1 | protein_coding | deleterious(0.01) | possibly_damaging(0.654) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
DIRC2 | deletion | Frame_Shift_Del | c.1359delN | p.Leu454CysfsTer75 | p.L454Cfs*75 | Q96SL1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
DIRC2 | SNV | Missense_Mutation | c.1348N>T | p.Pro450Ser | p.P450S | Q96SL1 | protein_coding | tolerated(0.1) | benign(0.046) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
DIRC2 | SNV | Missense_Mutation | novel | c.919N>G | p.Leu307Val | p.L307V | Q96SL1 | protein_coding | deleterious(0.02) | possibly_damaging(0.717) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DIRC2 | SNV | Missense_Mutation | c.652N>C | p.Glu218Gln | p.E218Q | Q96SL1 | protein_coding | tolerated(0.57) | benign(0.003) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
DIRC2 | SNV | Missense_Mutation | c.643C>T | p.Leu215Phe | p.L215F | Q96SL1 | protein_coding | tolerated(0.64) | benign(0.006) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
DIRC2 | SNV | Missense_Mutation | c.524N>G | p.Ser175Cys | p.S175C | Q96SL1 | protein_coding | deleterious(0.01) | possibly_damaging(0.697) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
DIRC2 | SNV | Missense_Mutation | c.496N>A | p.Ala166Thr | p.A166T | Q96SL1 | protein_coding | tolerated(0.12) | benign(0.153) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DIRC2 | SNV | Missense_Mutation | novel | c.644N>G | p.Leu215Arg | p.L215R | Q96SL1 | protein_coding | tolerated(0.28) | benign(0.179) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
DIRC2 | SNV | Missense_Mutation | c.1000N>A | p.Ala334Thr | p.A334T | Q96SL1 | protein_coding | tolerated(0.25) | benign(0.372) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |